Theralase Technologies (CVE:TLT) Trading Down 15.8% – Here’s Why

Theralase Technologies Inc. (CVE:TLT)’s stock price fell 15.8% on Tuesday . The stock traded as low as C$0.32 and last traded at C$0.32. 116,882 shares changed hands during trading, an increase of 1% from the average session volume of 115,945 shares. The stock had previously closed at C$0.38.

Theralase Technologies Stock Down 18.4 %

The company has a market cap of C$76.12 million, a PE ratio of -19.00 and a beta of 1.36. The company has a fifty day moving average of C$0.18 and a two-hundred day moving average of C$0.18. The company has a debt-to-equity ratio of 20.58, a quick ratio of 3.40 and a current ratio of 1.21.

Theralase Technologies (CVE:TLT) last released its quarterly earnings results on Monday, August 12th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$0.10 million for the quarter. As a group, analysts anticipate that Theralase Technologies Inc. will post -0.05 earnings per share for the current fiscal year.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.